enrotron 50 mg/ml solution for injection for cattle, sheep, goats, pigs, dogs and cats
animedica gmbh - enrofloxacin - solution for injection - 50 milligram(s)/millilitre - enrofloxacin
enroquin- enrofloxacin tablet, chewable
dechra veterinary products llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enroquin flavored tablets (enrofloxacin) are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enroquin flavored tablets are indicated for use in dogs and cats. contraindications: enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or
enroflox 100- enrofloxacin injection, solution
mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle - single-dose therapy: enroflox 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis . cattle - multiple-day therapy: enroflox 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine: enroflox 100 is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis , bordetella bronchiseptica and mycoplasma hyopneumoniae . enroflox 100 is indicated for the control of colibacillosis in groups or pens of weaned pig
enrofloxacin flavored- enrofloxacin tablet
butler animal health supply, llc dba covetrus north america - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.
enroquin- enrofloxacin tablet, chewable
dechra vet products, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enroquin (enrofloxacin) flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enroquin flavored tablets are indicated for use in dogs and cats. contraindications: enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or g
enroxil 100 mg/ml solution for injection for cattle and pigs
krka, d.d., novo mesto - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin - cattle, pigs - antibacterial
enroxil max 100 mg/ml solution for injection for cattle
krka, d.d., novo mesto - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin - cattle - antibacterial
baytril® (enrofloxacin) antibacterial injectable solution 2.27% for dogs only
bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar
enrofloxacin medimarket 5% veterinay
a.l. medi-market ltd. - enrofloxacin - solution for injection - enrofloxacin 50 mg / 1 ml - in calves:treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of pasteurella multocida, mannheimia haemolytica and mycoplasma spp. treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of escherichia coli. treatment of septicaemia caused by enrofloxacin susceptible strains of escherichia coli. treatment of acute mycoplasma-associated arthritis due to enrofloxacin susceptible strains of mycoplasma bovis.only after the sensitivity of the bacteria has been proven and it has been found that there is no alternative treatment (proven resistance to other agents).
enrofloxacin antibacterial injectable solution- enrofloxacin injection
dechra vet products, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. contraindications: enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.